Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H18ClNS |
Molecular Weight | 315.86 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CC\C=C1\C2=CC=CC=C2SC3=C1C=C(Cl)C=C3
InChI
InChIKey=WSPOMRSOLSGNFJ-AUWJEWJLSA-N
InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7-
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14065076Curator's Comment: description was created based on several sources, including, http://www.mentalmeds.org/prescription_meds/Truxal.html,
https://www.ncbi.nlm.nih.gov/pubmed/24071734
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14065076
Curator's Comment: description was created based on several sources, including, http://www.mentalmeds.org/prescription_meds/Truxal.html,
https://www.ncbi.nlm.nih.gov/pubmed/24071734
Chlorprothixene (Taractan, Tarasan, Truxal) is a thioxanthine derivative developed by Lundbeck for the treatment of psychotic disorders. The drug exerts its activity by binding to and inhibiting serotonin receptors, dopamine receptors, muscarinic acetylcholine receptor, histamine H1 receptor and alpha1-adrenergic receptor.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2056 |
18.0 nM [Ki] | ||
Target ID: CHEMBL2096904 |
|||
Target ID: CHEMBL2094251 |
|||
Target ID: P35367 Gene ID: 3269.0 Gene Symbol: HRH1 Target Organism: Homo sapiens (Human) |
3.75 nM [Ki] | ||
Target ID: CHEMBL2094109 |
|||
Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) |
3.4 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TRUXAL Approved UseTo treat psychosis. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1140253/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORPROTHIXENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
187 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1140253/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORPROTHIXENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1140253/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORPROTHIXENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1800 mg 1 times / day multiple, oral (max) Highest studied dose Dose: 1800 mg, 1 times / day Route: oral Route: multiple Dose: 1800 mg, 1 times / day Sources: |
unhealthy, 25-49 years n = 7 Health Status: unhealthy Age Group: 25-49 years Sex: M+F Population Size: 7 Sources: |
Disc. AE: Polyneuropathy... AEs leading to discontinuation/dose reduction: Polyneuropathy (7 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Polyneuropathy | 7 patients Disc. AE |
1800 mg 1 times / day multiple, oral (max) Highest studied dose Dose: 1800 mg, 1 times / day Route: oral Route: multiple Dose: 1800 mg, 1 times / day Sources: |
unhealthy, 25-49 years n = 7 Health Status: unhealthy Age Group: 25-49 years Sex: M+F Population Size: 7 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 27.47 uM] | ||||
yes [IC50 42 uM] | ||||
yes [IC50 74 uM] | ||||
yes [IC50 77.8 uM] | ||||
yes [Inhibition 20 uM] | ||||
yes [Inhibition 20 uM] | ||||
yes [Inhibition 20 uM] | ||||
yes [Ki 31.4 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. | 1986 Dec |
|
A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. | 2013 Feb |
Sample Use Guides
The usual adult dose is 15-100 mg (mild to moderate symptoms) or 100-400 mg (severe symptoms).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2444901
70 uM of cis-chlorprothixene produced approximately 50% inhibition of axonal transport measured in vitro in spinal nerves of the bullfrog.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
||
|
WHO-VATC |
QN05AF03
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
||
|
WHO-ATC |
N05AF03
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2406
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | RxNorm | ||
|
50931
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
667467
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
C65325
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL908
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
m3464
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
18720
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
113-59-7
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
9S7OD60EWP
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
DTXSID4022810
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
100000081895
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
CHLORPROTHIXENE
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
3651
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
2808
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
DB01239
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
886
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
623
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
204-032-8
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
SUB06210MIG
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY | |||
|
D002749
Created by
admin on Sat Dec 16 17:26:04 GMT 2023 , Edited by admin on Sat Dec 16 17:26:04 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)